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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract In this study, we designed a novel colorimetric method to detect multidrug resis-
tance in Mycobacterium tuberculosis isolates. The assay of loop-mediated isothermal amplifi-
cation (LAMP) is used to amplify target DNA from multidrug-resistant M. tuberculosis isolates,
and enzyme-linked immunosorbent assay (ELISA) is used for the colorimetric determination.
This method is designed based on point mutation at the hot spot region in target drug-
resistant gene using LAMP-polymerase chain reaction (PCR), hybridization, and thermal
melting for differentiating homoduplex DNA (drug-susceptible stain) and heteroduplex DNA
(resistance mutant). From ELISA colorimetric detection, color change developed in drug-
susceptible strains, and colorless result appeared in resistance mutants. A comparison of this
LAMP-PCR-hybridizationethermal melteELISA (LAMPeTMeELISA) method with the automated
BACTEC MGIT 960 system showed that the sensitivity of this molecular analysis of resistance to
isoniazid, rifampin, amikacin, and ciprofloxacin in M. tuberculosis was 92.3%, 95.3%, 93.1%,
and 91.4%, respectively. This method for detection of resistance to isoniazid, rifampin, amika-
cin, and ciprofloxacin in M. tuberculosis showed a specificity of 95.5e98.2% and a test effi-
ciency of 93.2e96.8%. This LAMPeTMeELISA method will be a useful tool for rapid diagnosis
(within 1 working day) and cost-effectiveness (US$15/reaction) to detect resistance to isoni-
azid, rifampin, amikacin, and ciprofloxacin via katG, inhA and mabA-inhA promoter, rpoB,
rrs, gyrA, and gyrB genes in M. tuberculosis isolates.t of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical
st Road, Kaohsiung 807, Taiwan.
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Taiwan LLC. All rights reserved.Table 1 Multidrug-resistant Mycobacterium tuberculosis
isolates used in this study.
Strain Resistance pattern No. of isolates
M. tuberculosis
isolates
INHr RIFr CIPr ANr 16
INHr RIFr 63
INHr RIFr CIPr 32
INHr 25
RIFr 10
INHr RIFr ANr 9
INHr CIPr 10
ANr 4
M. tuberculosis
H37Rv
Susceptible to all
drugs tested
Susceptible to all
drugs tested
52
1
Total 222
AN Z amikacin; CIP Z ciprofloxacin; INH Z isoniazid;
r Z resistance; RIF Z rifampin.Introduction
Multidrug-resistant (MDR) and extensively drug-resistant
(XDR) tuberculosis (TB) is a major cause of death among in-
fectious diseases in the world.1 In Taiwan, the prevalence of
MDR-TB and XDR-TB is approximately 3.2e8.2.3% and
0.5e1.1%, respectively.2 There is an urgent need for a new
strategy for the rapid diagnosis of MDR-TB and XDR-TB to
establish an effective treatment regimen. In current drug-
susceptibility testing, it takes from weeks to months to di-
agnose MDR-TB and XDR-TB. However, genetic testing
methods used to detect drug resistance in Mycobacterium
tuberculosis isolates are an attractive approach to provide a
significant choice for MDR-TB and XDR-TB treatment.3
Recently, loop-mediated isothermal amplification (LAMP)
assay has been designed as a rapid detection of resistance
gene in MDR M. tuberculosis isolates.4 Gene loci involved in
conferring drug resistance in M. tuberculosis to isoniazid
(INH), rifampin (RIF), amikacin (AN), and ciprofloxacin (CIP)
are associated with mutation frequency in the katG
(60e70%), inhA (21e34%), promoter of mabA-inhA operon
(10e15%), rpoB (96e100 %), rrs (75e94.2 %), gyrA and gyrB
(42e100 %), respectively.5e9 To date, high-resolution DNA
melting curve analysis has been applied for identification of
mutations in polymerase chain reaction (PCR) products as a
rapid scanning method for known and unknown sequence
alterations and genotyping.10e12 Based on the melting anal-
ysis of DNA, the instability of heteroduplexes results in a
lower Tm than that of homoduplexes.
13,14 Homoduplex DNA
was identified by the high-temperature melting curve dif-
ference than that of low-temperature heteroduplex DNA.
Thermal melting of DNA was commonly monitored by UV
absorbance, fluorescence, and curve analysis.15 In this LAMP-
PCR-hybridizationethermal melteenzyme-linked immuno-
sorbent assay (LAMPeTMeELISA) method, we describe a
novel ELISAmethod for thedetectionof thermalmeltingDNA.
The aim of this study was to develop and evaluate a
thermal melting-based method combined with colorimetric
detection for the rapid identification of multidrug resistance
in M. tuberculosis isolates. After LAMP reaction and internal
PCR,wild-type capture probes labeledwith biotin hybridized
with the single-stranded (SS) amplicons obtained from DNA
denaturation of PCR products. Homoduplex DNA is generated
if the SS amplicons do not contain any mutations. By
contrast, M. tuberculosis isolates have mutations within the
SS amplicons, resulting in the formation of heteroduplex
DNA. With thermal resolution melting temperature differ-
ence, incubation at 78C was used to differentiate the het-
eroduplex DNA from the homoduplex DNA. The heteroduplex
DNAweremelted and removed. The homoduplex DNA of PCR
products in wild-type susceptible strain will generate a color
change, resulting in ELISA colorimetric detection. By
contrast, heteroduplex DNA that carried mutational-type
codons expressed a colorless reaction.Materials and methods
M. tuberculosis isolates and drug susceptibility
testing
A total of 222 clinical isolates ofM. tuberculosiswascollected
for this study. They comprised one strain of M. tuberculosis
H37Rv (ATCC 27294) as well as 52 susceptible and 169 resis-
tant clinical isolates of M. tuberculosis randomly selected
from patients with pulmonary TB at Kaohsiung Medical Uni-
versityHospital, Kaohsiung, Taiwanbetween2007 and2008 in
southern Taiwan (Table 1). M. tuberculosis H37Rv (ATCC
27294) was used as a drug-susceptible reference strain to
evaluate the specificity of this LAMPeTMeELISA method. As
shown in Table 1, 155 INH-resistant and 67 INH-susceptible,
130 RIF-resistant and 92 RIF-susceptible, 29 AN-resistant
and 193 AN-susceptible, 58 CIP-resistant, and 164 CIP-
susceptible M. tuberculosis isolates were used in this study.
Drug susceptibility testing of isolates of M. tuberculosis was
conducted using the BACTEC MGIT 960 system (Becton,
Dickinson, and Company, Sparks, MD, USA).
Isolation of genomic DNA
A single colony of M. tuberculosis isolates from Low-
ensteineJensen slant agarwas suspended in 300mL of distilled
water and heat-inactivated at 80C for 30 minutes. The total
DNA of mycobacterial isolates was extracted using the Mas-
terPure Complete DNA kit (Epicentre Biotechnologies,
Madison, WI, USA). For DNA extraction from sputum speci-
mens, samples (0.5e1.0 mL) were digested and decontami-
nated using the N-acetyl-L-cysteine-NaOH procedure. The
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buffer; 0.5 mL was used for culture of M. tuberculosis in
LowensteineJensen medium and the remaining 0.5 mL was
transferred to a sterile Eppendorf tube and inactivated by
heating at 80C for 30 minutes. Samples were then centri-
fuged, and the pellet was washed with sterile distilled water
three times. After centrifugation, the resulting pellet was
used for isolation of genomic DNA. The resulting mycobacte-
rial DNA product [1e10 copies of TB DNA (109 ng)] was then
subjected to the LAMPeTMeELISA method.Primers and probe design
LAMP primers were used to amplify the target genes in M.
tuberculosis isolates containing lower copy DNA from clin-
ical samples, and specific internal primers were used to
identify the target genes. A set of four LAMP primers,
comprising two outer (F3 and B3) and two inner [FIP (for-
ward inner primer) (F1c þ F2) and BIP (backward inner
primer) (B1c þ B2)], was designed on the basis of the
published sequence of M. tuberculosis H37Rv (wild-type;
GenBank accession no. BX842576), by using the LAMP
primer design support software program (Netlaboratory,
http://primerexplorer.jp/e/index.html; Table 2). Specific
internal primers and capture probes were also designed for
internal PCR and hybridization. DNA sequencing for muta-
tional hot-spot regions was performed with automated DNA
sequencing analysis of both strands of the PCR products,
using an ABI Prism Model 373 DNA sequencer through spe-
cific internal PCR primers (Table 2).
Solid-phase primers designed in our laboratory for detec-
tion of different resistance genes were listed as follows.
katG1102A (50-TTTTTTTTTT-GGGCTT GGGCT G GAAGAGCTC-
30), inhA181F (50-TTTTTTTTTT-CGAGGAGCACC TGGCC AGCT T
G-30), mabA3221F (50-TTTTTTTTTT-CCTCGCTGCCCAGAAAG
GGA-30), rpoB 1201F (50-TTTTTTTTTT-GAGGCGATCACACCGC
AGAC-30), rrs 1283Ft (50-TTTTTTTTTT-C GGTCTCAGTTCG-
GATCGGG-30), gyrA157 Ft (50-TTTTTTTTTT-CGCCGGGTG
CTCTA TGCAA-30), and gyrB 1381Ft (50-TTTTTTTTTT-GCCC
GGCAAGCTGGCCGATTGC-30) were used for target-specific
amplification in katG, inhA, mabA-inhA promoter, rpoB, rrs,
gyrA, and gyrB, respectively. These solid-phase primers were
covalently bound in the NucleoLink tube (Thermo Scientific
Nunc, Thermo Fisher Scientific Inc., USA). The programs of
solid-phase primers binding to nucleololink wells were per-
formed as follows. Carbodiimide condensation reaction re-
agents was prepared by adding 1.63 mg of 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide into 8.5 mL 1 M 1-meth-
ylimidazole, and then adding 0.85 mL solid-phase primer
(1000 ng/mL) and 840 mL of 18 MU ddH2O. A total of 50 mL
carbodiimide condensation reaction reagents was put into the
well of NucleoLink tubes (Nalge Nunc International, Naper-
ville, IL, USA), and sealed with the Nunc Tape 8 (Nalge Nunc
International), and then incubated at 50C for 5 hours to allow
specific primers covalently binding with the NucleoLink tubes.
After heating incubation, the reaction tubes were washed
three times with 150 mL of 0.4 M NaOHe0.25% Tween 20 (50C)
to remove noncovalently bound primers. After cleaning, the
NucleoLink tubes were placed in an oven (set at 50C) for
15 minutes and then washed three times for 5 minutes with a
DIAPOPS (Detectionof ImmobilisedAmplifiedProduct inaOne-Phase System) buffer (80 mM TriseHCl, 20 mM Tris base,
150 mM NaCl, 0.1% Tween 20, pH 7.5). Finally, the NucleoLink
tubeswere driedwith paper towels, placed in ziplock bag, and
stored at 4C for up to 2 months.Establishment of colorimetric detection in one tube
of the LAMPeTMeELISA method
This technique is separated into three steps (Fig. 1). Step 1
is sample preparation of DNA extraction obtained from MDR
M. tuberculosis isolates. Step 2 is the LAMP-PCR-hybrid-
izationethermal melt procedure. Step 3 is ELISA colori-
metric detection. The details were designed and carried
out as follows. LAMP and PCR reaction mixture containing
LAMP primer sets, specific internal PCR primers, and
mycobacterial DNA template were added in the same
NucleoLink tube. The mixture was incubated at 65C for
30 minutes to perform LAMP reaction and then PCR assay.
After LAMP reaction, PCR with specific internal primers of
the resistance gene for detection of mutation was per-
formed using LAMP products as the template DNA. After
LAMPePCR, NucleoLink tubes were washed with DIAPOPS
buffer to remove noncovalently bound amplicons. Next,
denature solution (0.2 M NaOH with 0.1% Tween 20) was
added for DNA denaturation. Unbound SS amplicons were
removed by washing three times in DIAPOPS buffer.
Internal capture probes of thewild type of the resistance-
associated genes labeledwith biotinwere added to eachwell
for hybridization assays at 50C for 1 hour to hybridize with
the SS amplicons linking in the NucleoLink tubes. Homo-
duplex DNA was generated if the SS amplicons linking in the
NucleoLink tubes belonged to wild-type susceptible strain
samples. By contrast, M. tuberculosis isolates have muta-
tions within the SS amplicons, resulting in the formation of
heteroduplexes in the hybridization assays. Between the
thermal resolution melting temperature differences, the
NucleoLink tubes were then incubated between 75C and
78C for 1 hour to differentiate the heteroduplexes showing
low-resolution-melting temperature from the homoduplex
DNA exhibiting high-resolution-melting temperature. The
low-resolution-melting heteroduplex DNA were melted and
removed by washing three times in DIAPOPS buffer. Strep-
tavidineperoxidase was diluted to 1:2000 in DIAPOPS buffer,
and 100 mL was added to each tube. The tubes were incu-
bated at 37C for 1 hour. After incubation, the wells were
washed three times, soaked for 5minutes, andwashed three
more times with DIAPOPS buffer. Then, 100 mL of ABTS
(Roche Diagnostic GmbH, Roche Molecular Biochemicals,
Mannheim, Germany) was added to each tube.
Color development was allowed to proceed for 15 mi-
nutes in the dark at room temperature, and then optical
density (OD) values reading was done in an ELISA plate
reader (Anthos HT1; Anthos Labtec Instruments, Salzburg,
Austria) at 405 nm, with the reference filter at 492 nm. The
wild-type PCR products of M. tuberculosis DNA will
generate colorful products in ELISA colorimetric detection
after the hybridization detection process. However, drug-
resistant isolates that carried any mutational codons in
different resistance genes express a colorless reaction
resulting from the hybridization product melted by a spe-
cific resolution melting temperature.
Table 2 LAMP primers, specific internal PCR primers and capture probes used in this study.
Target genes (gene ID) LAMP primer setsa Internal PCR primer and capture probe (codons and nucleotides detected)
katG (885638) F3:50-AGGCTGCTCCGCTGGA-30
B3:50-ACGGGTCCGGGATGGT-30
FIP:50-GATGCCGCTGGTGATCGCGTC-
GATGGGCTTGGGCTGGAAG-30
BIP:50-TCGAGATCCTGTACGGCTACG-
ATCCTTGGCGGTGTATTGC-30
KG888F:
50-GGGCTTGGGCTGGAAGAGCTC-30
KG1102R:
50-ACGGGTCCGGGATGGT-30
Probe katG 937 (codons 313e320):
50-TACGACCTCGATGCCGCTGGTGAT-30
mabA-inhA promoter (JX975615) F3: 50-GTTCCCGCCGGAAATCG-30
B3: 50-GTGACGGCCACCTTGTG-30
FIP: 50-CAGTCACCCCGACAACCTATCG-
TTACGCTCGTGGACATACCG-30
BIP: 50-GAAGGGGCCAAACCCCCATTC-
GGCTGTGCGATCGCCAG-30
mabA 56F:
50-CCTCGCTGCCCAGAAAGGGA-30
mabA 284R:
50-ATCCCCCGGTTTCCTCCGGT -30
Probe mabA99 (nt 1 to 25): 50-CCCGACAACCTATCGTCTCGCCGCG-30
inhA (886523) F3: 50-TCCGGTGCGGTCATCC-30
B3: 50-GAATCAGCCGCAGCCG-30
FIP: 50-GTTTGCCGTCCAGCAGTCCT-
TGGGTATGGGCCACTGAC-30
BIP: 50-TCATCACCGACTCGTCGATCG-30
CACCCGGTGAGCACCAG-30
InhA222F:
50-CGAGGAGCACCTGGCCAGCTTG -30
InhA450R:
50-GTCGAAGTCCATGCCGACGATG-30
Probe inhA491 (codons 93e98): 50-CATGAACCCAATCGAATGCACCACC-30
rpoB (888164) F3: 50-GGCTCGCTGTCGGTGTAC-30
B3: 50-TCCATGTAGTCCACCTCAGA-30
FIP: 50-GCTAACCACGCCGTCGACCA-
GTCAACCCGTTCGGGTTCA-30
BIP: 50-CGATGCGGACGGTCGCTT-
GGCACGTACTCCACCTCG-30
RpoB 1210F:
50-GAGGCGATCACACCGCAGAC-30
RpoB 2472R:
50-TGCACGTCGCGGACCTCCAG-30
Probe rpoB2369 (codons 511e518): 50-GTTCTGGTCCATGAATTGGCTCAGC-30
Probe rpoB2399 (codons 521e528): 50-GCGCTTGTGGGTCAACCCCGACAGC-30
Probe rpoB242420 (codons 528e535): 50-GGGCCCCAGCGCCGACAGTCGGCGC-30
rrs (2700429) F3: 50-CGGAGTCGCTAGTAATCGC-30
B3: 50-GCTCAGAAAGGAGGTGATCC-30
FIP: 50-ACCGACTTTCATGACGTGACGG-
AACGCTGCGGTGAATACG-30
BIP: 50-CTAACCCTCGGGAGGGAGCT-
ACCTTCCGGTACGGCTAC-30
rrs1394: 50-TTACCGACTTTCATGACGTGACGGG-30
rrs1471: 50-TTGTTACGACTTCGTCCCAATCGCC-30
gyrA (887105) F3: 50-GGCTCAAGCCCGTGCA-30
B3: 50-GGTGGGTCATTGCCTGG-30
FIP: 50-ACTTGGCGTGGCTGCGGTC-
GCCGGGTGCTCTATGCA-30
BIP: 50-GATCTACGACAGCCTGGTGCGC-
CGAGCCGAAGTTGCCCT-30
gyrA263: 50-CCGTGCGGGTGGTAGTTGCCCATGG-30
gyrA287: 50-AGGCTGTCGTAGATCGACGCGTCGC-30
gyrB (887081) F3:: 50-TCCAGGCGATACTTCCGC-30
B3: 50-GTTGGCCGTCAACATCGG-30
FIP: 50-GCCGTGATGATCGCCTGAACTT-
GTGGAGAAAGCGCGCATC-30
BIP: 50-CACCGGGATCCACGACGAGT-
GCCATCAGCACGATCTTGT-30
gyrB 1481: 50-CGCCGGCCGAGTCACCTTCTACGAC-30
gyrB 1551: 50-TTGATG ATCTTGCCGCGCAGCGGAA-30
gyrB 1600: 50-GCCTGAACTTCGGTGTTCTTTAGCA-30
LAMP Z loop-mediated isothermal amplification; PCR Z polymerase chain reaction.
a FIP (forward inner primer): (F1c þ F2); BIP (backward inner primer): (B1c þ B2).
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Figure 1 Flowchart of the LAMP-PCR-hybridizationethermal melteELISA method. This method is separated into three steps. Step
1 is sample preparation of DNA extraction. Step 2 is LAMP-PCR-hybridizationethermal melting. LAMP and PCR are used for target
DNA amplification. Step 3 is ELISA colorimetric detection. Results where color developed represent susceptible strains and the
colorless results are resistance mutants. ELISA Z enzyme-linked immunosorbent assay; LAMP Z loop-mediated isothermal
amplification; PCR Z polymerase chain reaction.
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Data analysis of the LAMPeTMeELISA method was deter-
mined as follows. Sensitivity Z No. of drug-resistant iso-
lates with LAMP-positive/(No. of drug-resistant isolates
with LAMP-positive þ No. of drug-resistant isolates with
LAMP-negative). Specificity Z No. of drug-susceptible iso-
lates with LAMP-negative/(No. of drug-susceptible isolates
with LAMP-positive þ No. of drug-susceptible isolates with
LAMP-negative). Test efficiency Z (No. of drug-resistant
isolates with LAMP-positive þ No. of drug-susceptible iso-
lates with LAMP-negative)/No. of all isolates tested.Results
Mutational detection of katG, inhA, mabA
promoter, rpoB, rrs, gyrA, and gyrB in MDR M.
tuberculosis isolates
Our results are the first demonstration of using the ELISA
method to express mutations in those resistance genes
involved in resistance to isoniazid, rifampin, amikacin, and
ciprofloxacin in M. tuberculosis isolates. Genetic poly-
morphisms of katG, inhA, mabA promoter, rpoB, rrs, gyrA,
and gyrB were associated with resistance to isoniazid,
rifampin, amikacin, and ciprofloxacin, individually.
Furthermore, the results of the LAMPeTMeELISA methodagreed well with those produced using the DNA sequencing
method for mutational patterns of target genes (Table 3).
Cutoff value of the LAMPeTMeELISA method
The cutoff values (Ecutoff) were calculated as the mean
absorbance (A405) values of OD plus 3 standard deviations
(SD) (average OD450 value þ 3SD) for the interpretation of
the LAMPeTMeELISA method. The cutoff values for this
method were calculated from the results among 222 clinical
isolates of M. tuberculosis and reference strains of M.
tuberculosis H37Rv. In this study, the cutoff value for the
mutational hot spots of katG, inhA, mabA-inhA promoter,
rpoB, rrs, gyrA, and gyrB was established as 0.188, 0.107,
0.201, 0.171, 0.081, 0.10, and 0.233, respectively. For the
wild type of drug-susceptible M. tuberculosis, the ELISA
(OD450) value is 0.89e9.99.
Sensitivity, specificity, and test efficiency of the
LAMPeTMeELISA method
In a comparison of the LAMPeTMeELISA method with the
automated BACTEC MGIT 960 system, the sensitivity of this
molecular analysis for resistance to isoniazid, rifampin,
ciprofloxacin, and amikacin in M. tuberculosis was 92.2%,
94.7%, 91.3%, and 92.9%, respectively. This method for
detection of drug resistance to isoniazid, rifampin, cipro-
floxacin, and amikacin in M. tuberculosis showed a
Table 3 Genetic mutations of nucleotides and amino acids changes in katG, rpoB, inhA, mabA promoter, rrs, gyrA and gyrB
gene associated with 155 INH-resistant, 130 RIF-resistant, 29 AN-resistant, and 58 CIP-resistant M. tuberculosis isolates.
Mutations of codons or nucleotides in Nucleotide (amino acid) change No. of isolates
INH-resistant strain
katG 315 AGC/ACC (Ser/Thr) 50
katG 315 AGC/AAC (Ser/Asn) 31
inhA94 TCG/GCG (Ser/Ala) 7
inhA94 TCG/TTG (Ser/Leu) 5
inhA94 TCG/TGG (Ser/Trp) 3
inhA95 ATT/CTT (Ile/Pro) 15
mabA-inhA promoter (15) C/T 23
mabA-inhA promoter (8) T/C 8
mabA-inhA promoter (8) and (17) T/C and G/T 1
No mutation observed 12
RIF-resistant strain
rpoB516 GAC/GTC (Asp/Val) 26
rpoB516 GAC/TTC (Asp/Phe) 17
rpoB526 CAC/TAC (His/Tyr) 14
rpoB526 CAC/CGC (His/Arg) 7
rpoB526 CAC/CAA (His/Gln) 2
rpoB529 CGA/CGC 2
rpoB531 TCG/TTG (Ser/Leu) 56
No mutation observed 6
AN-resistant strain
rrs1400 A/G 27
No mutation observed 2
CIP-resistant strain
gyrA 90 GCG/GTG (Ala/Val) 5
gyrA 91 TCG/CCG (Ser/Pro) 8
gyrA 94 GAC/GGC (Asp/Gly) 16
gyrA 94 GAC/GCC (Asp/Ala) 4
gyrA 94 GAC/GCA (Asp/Ala) 3
gyrA 94 GAC/AAC (Asp/Asn) 15
gyrB538 AAC/AAA (Asn/Lys) 2
No mutation observed 5
AN Z amikacin; CIP Z ciprofloxacin; INH Z isoniazid; RIF Z rifampin.
Table 4 Comparison of the LAMP-PCR-hybridizationethermal melteELISA method and the MGIT system drug susceptibility
test.
MGIT system for drug
susceptibility test
No. of isolates (N Z 222)a Sensitivity (%) Specificity (%) Test
efficiency (%)LAMP positive LAMP negative
Isoniazid
Resistant 143 12 92.3 95.5 93.2
Susceptible 3 64
Rifampin
Resistant 124 6 95.3 97.8 96.4
Susceptible 2 90
Amikacin
Resistant 27 2 93.1 97.4 96.8
Susceptible 5 188
Ciprofloxacin
Resistant 53 5 91.4 98.2 96.4
Susceptible 3 161
ELISA Z enzyme-linked immunosorbent assay; LAMP Z loop-mediated isothermal amplification; PCR Z polymerase chain reaction.
a LAMP-positive: express colorless reaction; LAMP-negative: generate a colorful product.
Detection of multidrug-resistant M. tuberculosis 131
132 M.-F. Lee et al.95.5e98.2% specificity and a 93.2e96.8% test efficiency
(Table 4).
Discussion
In this study, the LAMPeTMeELISA method that we describe
here to replace the conventional PCR assay can amplify a
small amount of target DNA, and then works together with
the high-resolution thermal melting process to screen out
hot-spot mutation(s) in the resistance mutants of M.
tuberculosis isolates. For diagnostic applications, this is a
convenient method that can be performed within 1 working
day. This method can be applied for detection of mutations
associated with isoniazid resistance in katG, inhA, pro-
moter of mabA-inhA operon, rifampin resistance in rpoB,
amikacin resistance in rrs, and ciprofloxacin resistance in
gyrA and gyrB among M. tuberculosis isolates. However, the
mutational hot spots in the pncA gene for pyrazinamide
resistance are associated with multiple mutation sites, and
these variable hot spots could not be identified with a
limited probe.16
Furthermore, this LAMPeTMeELISA method can directly
and rapidly detect MDR M. tuberculosis isolates from clin-
ical specimens and clinical pure culture of M. tuberculosis
isolates. In this technique, the formation of heteroduplexes
in the hybridization comes from drug-resistant M. tuber-
culosis isolates with any hot spot point mutation(s) in
resistance genes. However, the phenomenon of rpoB gene
with silent mutation in codon CGA rpoB 529CGC (Arg/Arg)
also generated a false positive reaction in rifampin-
susceptible strains in our results.17,18 For detection of
clinical bacterial resistance, high-resolution melting has
been used as a mutation screening tool for the 23S rRNA
gene conferring macrolide resistance in Mycoplasma
pneumoniae,12 and the rpsL gene associated with strepto-
mycin resistance in M. tuberculosis.11 Curve analysis in
high-resolution melting technique has been described to
detect rifampicin, isoniazid, and streptomycin resistance in
M. tuberculosis clinical isolates.15 However, this is the first
report of a method of high-resolution thermal melting that
can detect the resistant mutants (as demonstrated by the
ELISA colorimetric detection) and can be operated rela-
tively cheaply (US$15/per reaction) using the PCR tech-
nique and ELISA reader.
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